CAJ | 학술논문

嵌合抗原受体修饰的 T 细胞在 B 淋巴细胞性白血病的治疗上已经取得突破性进展。近来，美国的几个临床研究中心报道了在这群患者中取得高达60％～80％临床反应率的良好疗效。这一振奋人心的结果带来了人们对免疫治疗新的热情和随之而来的大型制药公司和投资机构对这一领域的关注。免疫治疗需要在加强有效性的基础上，发展出更多的免疫治疗方法以增加这一治疗的多样性，才会对癌症这一对人类健康具有重大挑战的疾病产生真正的影响。我们相信随着转化医学研究的不断深入，21世纪将是免疫治疗走向癌症治疗中心舞台的时代。
감합항원수체수식적 T 세포재 B 림파세포성백혈병적치료상이경취득돌파성진전。근래，미국적궤개림상연구중심보도료재저군환자중취득고체60％～80％림상반응솔적량호료효。저일진강인심적결과대래료인문대면역치료신적열정화수지이래적대형제약공사화투자궤구대저일영역적관주。면역치료수요재가강유효성적기출상，발전출경다적면역치료방법이증가저일치료적다양성，재회대암증저일대인류건강구유중대도전적질병산생진정적영향。아문상신수착전화의학연구적불단심입，21세기장시면역치료주향암증치료중심무태적시대。
Clinical trials adopting chimeric antigen receptor -T lymphocytes (CAR-T) have made a breakthrough in treatment of B lymphocytic leukemia .Several clinical research centers in USA have reported excellent clinical response rate of 60%- 80% in these group of patients.This in turn drives a new wave of enthusiasm in immunotherapy , and comes along with interests and invest -ment from big pharmaceutical companies ,as well as investment firms.In order for immunotherapy to make a major impact in cancer therapy , it is required not only to enhance its effectiveness , but also to increase its variety.We believe, with more and more interests in translational medical research , the 21 Century will be an era that immunotherapy enters the center stage of cancer therapy .